Brain Cooling After Thrombectomy: Does Hypothermia Aid LVO Recovery?

Mechanical thrombectomy has transformed the acute management of LVO ischaemic stroke, achieving recanalisation rates that were unthinkable with intravenous thrombolysis alone. Yet recanalisation does not equal recovery. Roughly half of successfully recanalised patients are left with moderate-to-severe disability at 90 days, a gap attributed to reperfusion injury, haemorrhagic transformation, and progressive cerebral oedema in the hours after the procedure.¹ This gap has made the post-thrombectomy window an active target for neuroprotective strategies, of which targeted temperature management is among the most physiologically plausible.

The rationale is not new. Hypothermia reduces cerebral metabolic demand, attenuates excitotoxic glutamate release, limits free radical production, and suppresses inflammatory cascades, all mechanisms implicated in ischaemia-reperfusion injury.¹ Its success in post-cardiac-arrest care, where mild hypothermia (32 to 36 degrees Celsius) is guideline-endorsed, has encouraged its application to acute ischaemic stroke, though the two conditions differ substantially in the timing, territory, and reversibility of injury.¹

What the evidence currently shows

Translating hypothermia from the cardiac arrest setting to the stroke ward has proven difficult. Early trials of systemic cooling in awake stroke patients were hampered by shivering, haemodynamic instability, pneumonia risk, and difficulty achieving target temperatures before reperfusion, largely negating any theoretical neuroprotective window.¹ The post-thrombectomy context changes the calculus modestly: patients are already sedated or anaesthetised in many centres, and the reperfusion event is precisely timed, allowing cooling to be initiated at a defined moment relative to recanalisation.¹

Selective or localised brain cooling approaches, including intra-arterial cold saline infusion and endovascular cooling catheters, have been explored in early-phase work to reduce the systemic burden of temperature management while achieving meaningful reductions in brain temperature.¹ Feasibility studies have reported that target temperatures of approximately 33 to 35 degrees Celsius can be achieved in the peri-procedural period with manageable adverse event profiles, including acceptable rates of bleeding and infection.¹ However, these studies were not powered to detect differences in functional outcome, and the signal for benefit on the modified Rankin Scale at 90 days has not been replicated in a completed, adequately powered phase III randomised controlled trial.¹

The heterogeneity of LVO stroke, varying by occlusion site, collateral status, time to recanalisation, final infarct volume, and baseline neurological deficit, poses a particular problem for trial design. Subgroup analyses from feasibility data have hinted that patients with larger baseline diffusion-weighted imaging lesion volumes may derive less benefit, while those with good collateral flow and early recanalisation may represent a more receptive target population.¹ These remain hypothesis-generating observations only.¹

Safety signals warrant careful attention. Hypothermia prolongs the QT interval, increases infection susceptibility particularly pneumonia in ventilated patients, impairs platelet function, and can complicate haemostasis in a population already at risk of haemorrhagic transformation following thrombolysis or thrombectomy.¹ Rewarming protocols also carry risk: too-rapid rewarming can provoke rebound intracranial hypertension and cerebral oedema, effects that may be especially consequential in large territory infarcts.¹ Any future protocol will need to address rewarming rate as a primary safety endpoint, not a logistical afterthought.¹